Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Neuroblastoma 1Lymphoma, Mantle-Cell 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic, T-Cell 1Leukemia 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Breast Neoplasms 1Amyloidosis 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Lisaftoclax × Clear all
NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 1/2 Not yet recruiting
51 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07428486 2026-05-07

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡